哮喘生物制剂：肺功能、类固醇依赖性和病情恶化。

IF 2.7 3区医学 Q2 ALLERGY

Immunology and Allergy Clinics of North America Pub Date : 2024-10-08 DOI:10.1016/j.iac.2024.08.002

引用次数: 0

摘要

过去二十年来，多种靶向生物疗法的发展彻底改变了哮喘的治疗方法。目前，有 6 种单克隆抗体靶向参与哮喘病理生理学的特定炎症介质，它们共同为严重和难以控制的哮喘病例提供了支气管扩张剂和吸入或全身糖皮质激素之外的个性化治疗方案。这些药物包括抗IgE抗体奥马珠单抗、抗IL-5抗体mepolizumab和reslizumab、IL-5受体α拮抗剂benralizumab、IL-4受体α拮抗剂dupilumab和抗胸腺基质淋巴细胞生成素抗体tezepelumab。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Asthma Biologics

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunology and Allergy Clinics of North America 医学-过敏

CiteScore

5.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： Immunology and Allergy Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in immunology and allergy and is presented under the direction of an experienced guest editor. Topics include allergens, immunotherapy, anaphylaxis, asthma, drug allergy, eosinophilrelated disorders, food allergy, immunodeficiency states (non-HIV), basic science, mast cell disorders, rhinitis and sinusitis, and urticaria and angioedema. Immunology and Allergy Clinics of North America is published four times each year, in February, May, August, and November.